drugset
drugset / Trial / NCT05226455

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

NCT05226455 ↗

Phase 1/2 Active not recruiting 55 enrolled Groupe Francophone des Myelodysplasies AbbVie · collab
NaSingle-groupOpen-labelTreatment

Summary

Study to assess venetoclax + azacitidine and donor lymphocyte infusion (DLI) in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in relapse after allohematopoietic stem cell transplantation (AHSCT).

Timeline

Start
2022-11-23
Primary completion
2026-11-15
Completion
2027-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 50 mg/m2 —
Subject Azacitidine Other / unclassified 75 mg/m2 —
Subject Venetoclax Small molecule 50 mg Oral
Subject Venetoclax Small molecule 100 mg Oral
Subject Venetoclax Small molecule 200 mg Oral
Subject Venetoclax Small molecule 400 mg Oral

Indications

acute myeloid leukemia myelodysplastic syndrome